Lazard Asset Management LLC Has $73.09 Million Holdings in Omnicell, Inc. (NASDAQ:OMCL)

Lazard Asset Management LLC increased its holdings in shares of Omnicell, Inc. (NASDAQ:OMCL - Free Report) by 81.6% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,641,817 shares of the company's stock after acquiring an additional 737,536 shares during the period. Lazard Asset Management LLC owned about 3.54% of Omnicell worth $73,093,000 at the end of the most recent reporting period.

Several other institutional investors have also made changes to their positions in the business. Sumitomo Mitsui Trust Group Inc. lifted its holdings in shares of Omnicell by 93.3% during the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,450,416 shares of the company's stock valued at $64,573,000 after acquiring an additional 699,925 shares during the period. Dimensional Fund Advisors LP increased its position in shares of Omnicell by 31.6% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,642,626 shares of the company's stock worth $73,127,000 after purchasing an additional 394,820 shares in the last quarter. Victory Capital Management Inc. lifted its holdings in Omnicell by 32.9% during the 4th quarter. Victory Capital Management Inc. now owns 1,526,309 shares of the company's stock valued at $67,951,000 after purchasing an additional 377,883 shares during the last quarter. Oberweis Asset Management Inc. acquired a new position in Omnicell in the fourth quarter valued at about $14,834,000. Finally, Renaissance Technologies LLC grew its stake in Omnicell by 79.3% during the fourth quarter. Renaissance Technologies LLC now owns 456,343 shares of the company's stock worth $20,316,000 after buying an additional 201,831 shares during the last quarter. 97.70% of the stock is currently owned by institutional investors and hedge funds.

Omnicell Trading Down 0.4%

NASDAQ:OMCL traded down $0.12 during trading hours on Friday, hitting $27.96. 661,695 shares of the stock were exchanged, compared to its average volume of 558,784. The company has a market capitalization of $1.31 billion, a P/E ratio of 103.56, a price-to-earnings-growth ratio of 7.53 and a beta of 0.78. The company has a quick ratio of 1.22, a current ratio of 1.37 and a debt-to-equity ratio of 0.13. The company's 50 day moving average is $31.57 and its two-hundred day moving average is $39.64. Omnicell, Inc. has a twelve month low of $22.66 and a twelve month high of $55.75.

Omnicell (NASDAQ:OMCL - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The company reported $0.26 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.16 by $0.10. The business had revenue of $269.67 million for the quarter, compared to analyst estimates of $260.18 million. Omnicell had a return on equity of 3.82% and a net margin of 1.13%. The firm's revenue for the quarter was up 9.5% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.03 earnings per share. On average, sell-side analysts anticipate that Omnicell, Inc. will post 1.09 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have recently commented on OMCL shares. JPMorgan Chase & Co. reduced their target price on Omnicell from $44.00 to $36.00 and set a "neutral" rating on the stock in a report on Thursday, March 20th. Benchmark reduced their price objective on Omnicell from $62.00 to $40.00 and set a "buy" rating on the stock in a research note on Wednesday, May 7th. Wells Fargo & Company upgraded Omnicell from an "equal weight" rating to an "overweight" rating and increased their target price for the stock from $31.00 to $35.00 in a report on Wednesday. Finally, StockNews.com cut Omnicell from a "buy" rating to a "hold" rating in a report on Saturday, May 3rd. Four research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat.com, Omnicell currently has a consensus rating of "Hold" and a consensus target price of $46.50.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.